Dr. Saha is Senior Vice President, Global Head of Translational Medicine at Bristol-Myers Squibb. Previously, Dr. Saha was a venture partner at Atlas Venture, CMO of Synlogic and CEO of Delinia until its sale to Celgene in 2017. Earlier in his career, Dr. Saha was a consultant at McKinsey and head of the New Indications Discovery at Novartis. He received an MD, PhD from Johns Hopkins and is an alumnus of Harvard Business School, Oxford, and Caltech. Dr. Saha is dedicated to discovering and developing novel medicines and has published over 90 papers and patents.